Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
18 hedge funds and large institutions have $7.02M invested in Interpace Biosciences, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
125% more capital invested
Capital invested by funds: $3.12M → $7.02M (+$3.9M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
6% more funds holding
Funds holding: 17 → 18 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$934K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$769K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$364K |
| 4 |
JP Morgan Chase
New York
|
+$151K |
| 5 |
VF
Virtu Financial
New York
|
+$90.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$830K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$14K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$12K |
| 5 |
BA
Ballew Advisors
Jackson,
Mississippi
|
-$11K |
IDXG Hedge Fund Activity: Q3 2018 in Review
18 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2018, worth a combined $7.02M — up 125% from $3.12M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IDXG positions and 8 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $934K. The largest seller was Sabby Management, exiting entirely with an estimated $830K sold.
- 18 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2018, up from 17 in Q2 2018.
- Funds reported $7.02M of Interpace Biosciences, Inc. Common Stock stock for Q3 2018, up 125% quarter-over-quarter.
- 9 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2018 and 8 closed out, a net change of +1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2018 was Schonfeld Strategic Advisors, an estimated $934K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2018 was Sabby Management, an estimated $830K sold.
Based on aggregated 13F filings for Q3 2018.